Biosimilars are now a part of everyday clinical practice. The potential cost savings they offer create an opportunity to improve overall patient care. However, making the switch involves getting stakeholders on board and making sure robust monitoring systems are in place, an expert says. The concept of gain-share Speaking to the limbic at the ...
Stakeholder collaboration key to making the switch to biosimilars
25 Nov 2016
Sponsored by Pfizer Australia